文献速递血栓与止血造血干细胞移植与细胞治疗

生物工程改造血友病A特异性微血管移植物将全长FVIII递送入血流

Bioengineering hemophilia A-specific microvascular grafts for delivery of full-length factor VIII into the bloodstream.
PubMed 文献 · Blood Adv · 2019-01-01

研究利用piggyBac转座子系统将多拷贝全长F8基因导入血友病A患者尿液上皮细胞来源的诱导多能干细胞,高效分化为内皮细胞,在免疫缺陷血友病小鼠皮下植入后自组装成血管网络,将功能性FVIII直接递送入血流并纠正凝血缺陷。

要点

  • 非病毒体外基因治疗可实现全长F8在患者内皮细胞中过表达
  • 植入的工程化内皮细胞自组装成微血管并递送功能性FVIII入血
  • 植入物保持细胞 confinement,具可监测性和可逆性

核心结论

  • 概念验证研究表明,基于患者iPSC来源内皮细胞递送全长FVIII的体外基因治疗策略有望治疗血友病A。

研究设计与样本

  • 从血友病A患者尿液上皮细胞重编程获得诱导多能干细胞,用piggyBac转座子插入多拷贝全长F8,再分化为内皮细胞(HA-FLF8-iECs)。
  • 将HA-FLF8-iECs皮下植入免疫缺陷血友病(SCID-f8ko)小鼠,观察血管网络形成和FVIII递送。

主要发现

  • HA-FLF8-iECs能产生高水平FVIII。
  • 植入后HA-FLF8-iECs自组装成血管网络,新形成的微血管能将功能性FVIII直接递送入小鼠血流。
  • 该递送有效纠正了小鼠的凝血缺陷。

临床怎么用

  • 该策略为血友病A提供了一种无需病毒载体的自体体外基因治疗新思路。
  • 植入物保持细胞局限,便于监测和可逆性管理,可能降低安全风险。

局限性

  • 研究仅为概念验证,证据来自免疫缺陷血友病小鼠模型,尚未在患者中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hemophilia A (HA) is a bleeding disorder caused by mutations in the F8 gene encoding coagulation factor VIII (FVIII). Current treatments are based on regular infusions of FVIII concentrates throughout a patient's life. Alternatively, viral gene therapies that directly deliver F8 in vivo have shown preliminary successes. However, hurdles remain, including lack of infection specificity and the inability to deliver the full-length version of F8 due to restricted viral cargo sizes. Here, we developed an alternative nonviral ex vivo gene-therapy approach that enables the overexpression of full-length F8 in patients' endothelial cells (ECs). We first generated HA patient-specific induced pluripotent stem cells (HA-iPSCs) from urine epithelial cells and genetically modified them using a piggyBac DNA transposon system to insert multiple copies of full-length F8. We subsequently differentiated the modified HA-iPSCs into competent ECs with high efficiency, and demonstrated that the cells (termed HA-FLF8-iECs) were capable of producing high levels of FVIII. Importantly, following subcutaneous implantation into immunodeficient hemophilic (SCID-f8ko) mice, we demonstrated that HA-FLF8-iECs were able to self-assemble into vascular networks, and that the newly formed microvessels had the capacity to deliver functional FVIII directly into the bloodstream of the mice, effectively correcting the clotting deficiency. Moreover, our implant maintains cellular confinement, which reduces potential safety concerns and allows effective monitoring and reversibility. We envision that this proof-of-concept study could become the basis for a novel autologous ex vivo gene-therapy approach to treat HA.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Neumeyer J, Lin RZ, Wang K, et al. Bioengineering hemophilia A-specific microvascular grafts for delivery of full-length factor VIII into the bloodstream. Blood Adv. 2019. PMID: 31851760. doi:10.1182/bloodadvances.2019000848

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。